13 results on '"Véronique Guyonnet-Duperat"'
Search Results
2. In Silico, In Vitro and In Cellulo Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion
- Author
-
Delphine Lapaillerie, Cathy Charlier, Henrique S. Fernandes, Sergio F. Sousa, Paul Lesbats, Pierre Weigel, Alexandre Favereaux, Véronique Guyonnet-Duperat, and Vincent Parissi
- Subjects
SARS-CoV-2 ,COVID ,Spike/ACE2 complex ,Microbiology ,QR1-502 - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent responsible for the recent coronavirus disease 2019 (COVID-19) pandemic. Productive SARS-CoV-2 infection relies on viral entry into cells expressing angiotensin-converting enzyme 2 (ACE2). Indeed, viral entry into cells is mostly mediated by the early interaction between the viral spike protein S and its ACE2 receptor. The S/ACE2 complex is, thus, the first contact point between the incoming virus and its cellular target; consequently, it has been considered an attractive therapeutic target. To further characterize this interaction and the cellular processes engaged in the entry step of the virus, we set up various in silico, in vitro and in cellulo approaches that allowed us to specifically monitor the S/ACE2 association. We report here a computational model of the SARS-CoV-2 S/ACE2 complex, as well as its biochemical and biophysical monitoring using pulldown, AlphaLISA and biolayer interferometry (BLI) binding assays. This led us to determine the kinetic parameters of the S/ACE2 association and dissociation steps. In parallel to these in vitro approaches, we developed in cellulo transduction assays using SARS-CoV-2 pseudotyped lentiviral vectors and HEK293T-ACE2 cell lines generated in-house. This allowed us to recapitulate the early replication stage of the infection mediated by the S/ACE2 interaction and to detect cell fusion induced by the interaction. Finally, a cell imaging system was set up to directly monitor the S/ACE2 interaction in a cellular context and a flow cytometry assay was developed to quantify this association at the cell surface. Together, these different approaches are available for both basic and clinical research, aiming to characterize the entry step of the original SARS-CoV-2 strain and its variants as well as to investigate the possible chemical modulation of this interaction. All these models will help in identifying new antiviral agents and new chemical tools for dissecting the virus entry step.
- Published
- 2021
- Full Text
- View/download PDF
3. Targeting the mitochondrial trifunctional protein restrains tumor growth in oxidative lung carcinomas
- Author
-
Isabelle Redonnet-Vernhet, Nadège Bellance, Floriant Bellvert, Matthieu Thumerel, Nathalie Dugot-Senan, Mariana Figueiredo Rodrigues, Hamid Reza Rezvani, Hugues Begueret, Elodie Dumon, Fatima Mechta-Grigoriou, Rodrigue Rossignol, Didier Lacombe, Pauline Esteves, Giuseppe Punzi, Yann Kieffer, Julien Izotte, Nivea Dias Amoedo, Ciro Leonardo Pierri, Tony Lionel Palama, Saharnaz Sarlak, Benoit Rousseau, Jean-Marc Baste, Lara Gales, Stéphane Claverol, Emilie Obre, Alexis Dupis, Laetitia Dard, Véronique Guyonnet-Duperat, Walid Mafhouf, Cellomet [CHU Pellegrin, Bordeaux], CHU de Bordeaux Pellegrin [Bordeaux], Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) (U1211 INSERM/MRGM), Université de Bordeaux (UB)-Groupe hospitalier Pellegrin-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bordeaux (UB), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Unité de génétique et biologie des cancers (U830), Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Pellegrin, CHU de Bordeaux, Università degli studi di Bari Aldo Moro (UNIBA), Inserm U1035, Biotherapies des Maladies Genetiques et Cancers, Univ Bordeaux, CHU de Bordeaux, Pole de Biologie et Pathologie, Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse Biotechnology Institute (TBI), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Flow Cytometry Facility / TransBioMed Core [Bordeaux] (INSERM US005 - CNRS UMS 3427 - UB), Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Proteomics Core Facility (Protim), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Plateforme Génomique Santé Biogenouest®, Institut National de la Sante et de la Recherche Medicale (Inserm), National Council for Scientific and Technological Development (CNPq), Fondation ARC, French National Institute against cancer (Inca), Ligue nationale contre le cancer, ITN Marie Curie TRANSMIT (H2020-MSCA-ITN-2016) 722605, SIRIC-Brio2 (Project PRIME/IMS/COMMUCAN), CAPES, Canceropole GSO (Club Metabo-Cancer), Plan Cancer, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), TBM-Core [Bordeaux] (UMS3427 - INSERM US005), Université de Rennes (UR)-Plateforme Génomique Santé Biogenouest®, Astruc, Suzette, Institut National des Sciences Appliquées (INSA)-Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées (INSA)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and TBM-Core [Bordeaux] (CNRS UMS 3427 - INSERM US 005)
- Subjects
0301 basic medicine ,Lung Neoplasms ,Bioenergetics ,Trimetazidine ,Oxidative phosphorylation ,Mitochondrial trifunctional protein ,03 medical and health sciences ,0302 clinical medicine ,Drug Delivery Systems ,In vivo ,Cell Line, Tumor ,medicine ,Humans ,Beta oxidation ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,Electron Transport Complex I ,biology ,Chemistry ,Cancer ,General Medicine ,medicine.disease ,3. Good health ,Neoplasm Proteins ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,Adenocarcinoma ,Mitochondrial Trifunctional Protein, alpha Subunit ,Oxidation-Reduction ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,medicine.drug ,Research Article - Abstract
International audience; Metabolic reprogramming is a common hallmark of cancer, but a large variability in tumor bioenergetics exists between patients. Using high-resolution respirometry on fresh biopsies of human lung adenocarcinoma, we identified 2 subgroups reflected in the histologically normal, paired, cancer-adjacent tissue: high (OX+) mitochondrial respiration and low (OX-) mitochondrial respiration. The OX+ tumors poorly incorporated [F-18]fluorodeoxy-glucose and showed increased expression of the mitochondrial trifunctional fatty acid oxidation enzyme (MTP; HADHA) compared with the paired adjacent tissue. Genetic inhibition of MTP altered OX+ tumor growth in vivo. Trimetazidine, an approved drug inhibitor of MTP used in cardiology, also reduced tumor growth and induced disruption of the physical interaction between the MTP and respiratory chain complex I, leading to a cellular redox and energy crisis. MTP expression in tumors was assessed using histology scoring methods and varied in negative correlation with [F-18]fluorodeoxy-glucose incorporation. These findings provide proof-of-concept data for preclinical, precision, bioenergetic medicine in oxidative lung carcinomas.
- Published
- 2021
- Full Text
- View/download PDF
4. Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia
- Author
-
Claudie Bosc, Jean-Emmanuel Sarry, Marc Piechaczyk, Thomas Farge, Sonia Zaghdoudi, Mohsen Hosseini, Hamid Reza Rezvani, Véronique Guyonnet-Duperat, Clément Larrue, Mathilde Gotanègre, Nesrine Aroua, Pierre Luc Mouchel, Latifa Jarrou, Marie Sabatier, Christian Recher, Guillaume Bossis, Estelle Saland, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Transfert de gènes à visée thérapeutique dans les cellules souches, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Plate-forme de vectorologie, Université Bordeaux Segalen - Bordeaux 2-SFR TransBioMed, Institut de Génétique Moléculaire de Montpellier (IGMM), and Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)
- Subjects
0301 basic medicine ,Cancer Research ,Myeloid ,[SDV]Life Sciences [q-bio] ,Apoptosis ,Mice, SCID ,medicine.disease_cause ,Mice ,0302 clinical medicine ,Mice, Inbred NOD ,hemic and lymphatic diseases ,Molecular Targeted Therapy ,RNA, Neoplasm ,RNA, Small Interfering ,ComputingMilieux_MISCELLANEOUS ,Membrane Potential, Mitochondrial ,chemistry.chemical_classification ,biology ,Chemistry ,Cytarabine ,Myeloid leukemia ,Mitochondria ,Neoplasm Proteins ,3. Good health ,Leukemia, Myeloid, Acute ,Leukemia ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Myeloperoxidase ,Oxidation-Reduction ,medicine.drug ,Antimetabolites, Antineoplastic ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Oxidative phosphorylation ,03 medical and health sciences ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Peroxidase ,Reactive oxygen species ,Gene Expression Profiling ,medicine.disease ,Xenograft Model Antitumor Assays ,Hypochlorous Acid ,Oxidative Stress ,030104 developmental biology ,Drug Resistance, Neoplasm ,Cancer research ,biology.protein ,Reactive Oxygen Species ,Transcriptome ,Oxidative stress - Abstract
Chemotherapies alter cellular redox balance and reactive oxygen species (ROS) content. Recent studies have reported that chemoresistant cells have an increased oxidative state in hematologic malignancies. In this study, we demonstrated that chemoresistant acute myeloid leukemia (AML) cells had a lower level of mitochondrial and cytosolic ROS in response to cytarabine (AraC) and overexpressed myeloperoxidase (MPO), a heme protein that converts hydrogen peroxide to hypochlorous acid (HOCl), compared with sensitive AML cells. High MPO-expressing AML cells were less sensitive to AraC in vitro and in vivo. They also produced higher levels of HOCl and exhibited an increased rate of mitochondrial oxygen consumption when compared with low MPO-expressing AML cells. Targeting MPO expression or enzyme activity sensitized AML cells to AraC treatment by triggering oxidative damage and sustaining oxidative stress, particularly in high MPO-expressing AML cells. This sensitization stemmed from mitochondrial superoxide accumulation, which impaired oxidative phosphorylation and cellular energetic balance, driving apoptotic death and selective eradication of chemoresistant AML cells in vitro and in vivo. Altogether, this study uncovers a noncanonical function of MPO enzyme in maintaining redox balance and mitochondrial energetic metabolism, therefore affecting downstream pathways involved in AML chemoresistance. Significance: These findings demonstrate the role of myeloperoxidase in the regulation of ROS levels and sensitivity of AML cells to cytarabine, an essential chemotherapeutic backbone in the therapy of AML.
- Published
- 2019
- Full Text
- View/download PDF
5. CRISPR editing to mimic porphyria combined with light: A new preclinical approach for prostate cancer
- Author
-
Julian Boutin, Coralie Genevois, Franck Couillaud, Isabelle Lamrissi-Garcia, Veronique Guyonnet-Duperat, Alice Bibeyran, Magalie Lalanne, Samuel Amintas, Isabelle Moranvillier, Emmanuel Richard, Jean-Marc Blouin, Sandrine Dabernat, François Moreau-Gaudry, and Aurélie Bedel
- Subjects
MT: Regular Issue ,cancer gene therapy ,CRISPR ,porphyrin ,UROS ,porphyria ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Thanks to its very high genome-editing efficiency, CRISPR-Cas9 technology could be a promising anticancer weapon. Clinical trials using CRISPR-Cas9 nuclease to ex vivo edit and alter immune cells are ongoing. However, to date, this strategy still has not been applied in clinical practice to directly target cancer cells. Targeting a canonical metabolic pathway essential to good functioning of cells without potential escape would represent an attractive strategy. We propose to mimic a genetic metabolic disorder in cancer cells to weaken cancer cells, independent of their genomic abnormalities. Mutations affecting the heme biosynthesis pathway are responsible for porphyria, and most of them are characterized by an accumulation of toxic photoreactive porphyrins. This study aimed to mimic porphyria by using CRISPR-Cas9 to inactivate UROS, leading to porphyrin accumulation in a prostate cancer model. Prostate cancer is the leading cancer in men and has a high mortality rate despite therapeutic progress, with a primary tumor accessible to light. By combining light with gene therapy, we obtained high efficiency in vitro and in vivo, with considerable improvement in the survival of mice. Finally, we achieved the preclinical proof-of-principle of performing cancer CRISPR gene therapy.
- Published
- 2024
- Full Text
- View/download PDF
6. Preventing Pluripotent Cell Teratoma in Regenerative Medicine Applied to Hematology Disorders
- Author
-
Benoit Rucheton, François Béliveau, Aurélie Bedel, Véronique Guyonnet-Duperat, Hubert de Verneuil, Isabelle Moranvillier, Sandrine Dabernat, Benoit Rousseau, Isabelle Lamrissi-Garcia, François Moreau-Gaudry, and Bruno Cardinaud
- Subjects
0301 basic medicine ,Time Factors ,Survivin ,Cellular differentiation ,Mice, SCID ,Regenerative Medicine ,Hematopoietic stem cell ,0302 clinical medicine ,Translational Research Articles and Reviews ,Mice, Inbred NOD ,Induced pluripotent stem cell ,Genes, Transgenic, Suicide ,Hematopoietic Stem Cell Transplantation ,Imidazoles ,Teratoma ,Hematology ,General Medicine ,Caspase 9 ,Tumor Burden ,Gene Expression Regulation, Neoplastic ,Haematopoiesis ,Cell Transformation, Neoplastic ,Phenotype ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Safety ,Stem cell ,Pluripotent Stem Cells ,Induced Pluripotent Stem Cells ,Survivin inhibitor ,Biology ,Risk Assessment ,Tacrolimus ,Cell Line ,iCaspase‐9 ,03 medical and health sciences ,medicine ,Animals ,Humans ,Cell Proliferation ,Dose-Response Relationship, Drug ,Cell Biology ,Suicide gene ,Hematopoietic Stem Cells ,medicine.disease ,Hematologic Diseases ,Xenograft Model Antitumor Assays ,Thymidine kinase ,030104 developmental biology ,Cancer research ,Naphthoquinones ,Developmental Biology - Abstract
Iatrogenic tumorigenesis is a major limitation for the use of human induced pluripotent stem cells (hiPSCs) in hematology. The teratoma risk comes from the persistence of hiPSCs in differentiated cell populations. Our goal was to evaluate the best system to purge residual hiPSCs before graft without compromising hematopoietic repopulation capability. Teratoma risk after systemic injection of hiPSCs expressing the reporter gene luciferase was assessed for the first time. Teratoma formation in immune-deficient mice was tracked by in vivo bioimaging. We observed that systemic injection of hiPSCs produced multisite teratoma as soon as 5 weeks after injection. To eliminate hiPSCs before grafting, we tested the embryonic-specific expression of suicide genes under the control of the pmiR-302/367 promoter. This promoter was highly active in hiPSCs but not in differentiated cells. The gene/prodrug inducible Caspase-9 (iCaspase-9)/AP20187 was more efficient and rapid than thymidine kinase/ganciclovir, fully specific, and without bystander effect. We observed that iCaspase-9-expressing hiPSCs died in a dose-dependent manner with AP20187, without reaching full eradication in vitro. Unexpectedly, nonspecific toxicity of AP20187 on iCaspase-9-negative hiPSCs and on CD34+ cells was evidenced in vitro. This toxic effect strongly impaired CD34+-derived human hematopoiesis in adoptive transfers. Survivin inhibition is an alternative to the suicide gene approach because hiPSCs fully rely on survivin for survival. Survivin inhibitor YM155 was more efficient than AP20187/iCaspase-9 for killing hiPSCs, without toxicity on CD34+ cells, in vitro and in adoptive transfers. hiPSC purge by survivin inhibitor fully eradicated teratoma formation in immune-deficient mice. This will be useful to improve the safety management for hiPSC-based medicine.
- Published
- 2016
- Full Text
- View/download PDF
7. HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53
- Author
-
Jean-William Dupuy, Romano Silvestri, Francis Sagliocco, Melina Petrel, Nadine Thézé, Sandrine Fédou, Angélique Desplat, Anne-Aurélie Raymond, Véronique Guyonnet-Duperat, Katarzyna B. Hooks, Pierre Thiébaud, Caroline Capdevielle, Martin Hagedorn, Justine Charpentier, Christophe Grosset, Grosset, Christophe, Initiative d'excellence de l'Université de Bordeaux - - IDEX BORDEAUX2010 - ANR-10-IDEX-0003 - IDEX - VALID, Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Medicinal Chemistry and Technologies, Institut Pasteur, Fondation Cenci Bolognetti - Istituto Pasteur Italia, Fondazione Cenci Bolognetti, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Bordeaux Imaging Center (BIC), Université de Bordeaux (UB)-Institut François Magendie-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Physiopathologie du cancer du foie, TBM-Core [Bordeaux] (CNRS UMS 3427 - INSERM US 005), Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Génomique Fonctionnelle Bordeaux [Bordeaux] (CGFB), Institut Polytechnique de Bordeaux-Université de Bordeaux Ségalen [Bordeaux 2], This study was supported by grants from the Agence Nationale de la Recherche (ANR) in the frame of the 'Investments for the future' program, IdEx program Univ Bordeaux (reference ANR10-IDEX-03-02), and the following charity associations: Eva Pour La Vie, Aidons Marina, Fondation Flavien, E.S.C.A.P.E., Les Amis de Marius, Kaëna et les lapinours foundation, the Cassandra Contre la Leucémie association, Les Motards Solidaires and the Sphères foundantion. CC was supported by 'Fondation Groupama pour la santé' and Eva Pour La Vie., ANR-10-IDEX-0003,IDEX BORDEAUX,Initiative d'excellence de l'Université de Bordeaux(2010), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut François Magendie-Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), and Flow Cytometry Facility / TransBioMed Core [Bordeaux] (INSERM US005 - CNRS UMS 3427 - UB)
- Subjects
Proteomics ,Cancer Research ,Apoptosis ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Chick Embryo ,Histone Deacetylases ,Histones ,03 medical and health sciences ,chemistry.chemical_compound ,Histone H3 ,0302 clinical medicine ,Downregulation and upregulation ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Glioma ,Panobinostat ,Cell Line, Tumor ,medicine ,[SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology ,Animals ,Humans ,[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology ,Propidium iodide ,Child ,EBP50 ,IRSp53 ,030304 developmental biology ,0303 health sciences ,Cell growth ,HDACi ,Diffuse midline glioma ,medicine.disease ,chick chorioallantoic membrane ,diffuse midline glioma ,3. Good health ,Histone Deacetylase Inhibitors ,Oncology ,chemistry ,Tumor progression ,030220 oncology & carcinogenesis ,Cancer research ,Neurology (clinical) ,Histone deacetylase ,Pediatric Neuro-Oncology - Abstract
Background Diffuse midline glioma (DMG) is a pediatric malignancy with poor prognosis. Most children die less than one year after diagnosis. Recently, mutations in histone H3 have been identified and are believed to be oncogenic drivers. Targeting this epigenetic abnormality using histone deacetylase (HDAC) inhibitors such as panobinostat (PS) is therefore a novel therapeutic option currently evaluated in clinical trials. Methods BH3 profiling revealed engagement in an irreversible apoptotic process of glioma cells exposed to PS confirmed by annexin-V/propidium iodide staining. Using proteomic analysis of 3 DMG cell lines, we identified 2 proteins deregulated after PS treatment. We investigated biological effects of their downregulation by silencing RNA but also combinatory effects with PS treatment in vitro and in vivo using a chick embryo DMG model. Electron microscopy was used to validate protein localization. Results Scaffolding proteins EBP50 and IRSp53 were upregulated by PS treatment. Reduction of these proteins in DMG cell lines leads to blockade of proliferation and migration, invasion, and an increase of apoptosis. EBP50 was found to be expressed in cytoplasm and nucleus in DMG cells, confirming known oncogenic locations of the protein. Treatment of glioma cells with PS together with genetic or chemical inhibition of EBP50 leads to more effective reduction of cell growth in vitro and in vivo. Conclusion Our data reveal a specific relation between HDAC inhibitors and scaffolding protein deregulation which might have a potential for therapeutic intervention for cancer treatment.
- Published
- 2019
- Full Text
- View/download PDF
8. Cancer Cell Survival Following DNA Damage-mediated Premature Senescence Is Regulated by Mammalian Target of Rapamycin (mTOR)-dependent Inhibition of Sirtuin 1
- Author
-
Arianna L. Kim, Yucui Zhu, Jung Ho Back, Véronique Guyonnet-Duperat, Désirée Ratner, Hamid Reza Rezvani, and Mohammad Athar
- Subjects
Cell Survival ,Ultraviolet Rays ,DNA damage ,Mutation, Missense ,Apoptosis ,Biochemistry ,Minor Histocompatibility Antigens ,Mice ,Sirtuin 1 ,Cell Line, Tumor ,Animals ,Humans ,Phosphorylation ,Molecular Biology ,Cellular Senescence ,PI3K/AKT/mTOR pathway ,Adaptor Proteins, Signal Transducing ,Mice, Knockout ,Antibiotics, Antineoplastic ,biology ,Caspase 3 ,TOR Serine-Threonine Kinases ,Transcription Factor RelA ,Acetylation ,Regulatory-Associated Protein of mTOR ,Cell Biology ,Cell cycle ,Enzyme Activation ,Oxidative Stress ,Amino Acid Substitution ,Proto-Oncogene Proteins c-bcl-2 ,Doxorubicin ,Cancer cell ,Carcinoma, Squamous Cell ,Cancer research ,biology.protein ,Tumor Suppressor Protein p53 ,Carrier Proteins ,Cell aging ,DNA Damage ,Signal Transduction ,Deacetylase activity - Abstract
DNA-damaging agents can induce premature senescence in cancer cells, which contributes to the static effects of cancer. However, senescent cancer cells may re-enter the cell cycle and lead to tumor relapse. Understanding the mechanisms that control the viability of senescent cells may be helpful in eliminating these cells before they can regrow. Treating human squamous cell carcinoma (SCC) cells with the anti-cancer compounds, resveratrol and doxorubicin, triggered p53-independent premature senescence by invoking oxidative stress-mediated DNA damage. This process involved the mTOR-dependent phosphorylation of SIRT1 at serine 47, resulting in the inhibition of the deacetylase activity of SIRT1. SIRT1 phosphorylation caused concomitant increases in p65/RelA NF-κB acetylation and the expression of an anti-apoptotic Bfl-1/A1. SIRT1 physically interacts with the mTOR-Raptor complex, and a single amino acid substitution in the TOS (TOR signaling) motif in the SIRT1 prevented Ser-47 phosphorylation and Bfl-1/A1 induction. The pharmacologic and genetic inhibition of mTOR, unphosphorylatable S47A, or F474A TOS mutants restored SIRT1 deacetylase activity, blocked Bfl-1/A1 induction, and sensitized prematurely senescent SCC cells for apoptosis. We further show that the treatment of UVB-induced SCCs with doxorubicin transiently stabilized tumor growth but was followed by tumor regrowth upon drug removal in p53(+/-)/SKH-1 mice. The subsequent treatment of stabilized SCCs with rapamycin decreased tumor size and induced caspase-3 activation. These results demonstrate that the inhibition of SIRT1 by mTOR fosters survival of DNA damage-induced prematurely senescent SCC cells via Bfl-1/A1 in the absence of functional p53.
- Published
- 2011
- Full Text
- View/download PDF
9. FGFR3 has tumor suppressor properties in cells with epithelial phenotype
- Author
-
Marie Lafitte, Jeanne Ramos, Benoit Rousseau, Hubert de Verneuil, Geneviève Belleannée, Véronique Guyonnet-Duperat, Stéphane Garcia, François Moreau-Gaudry, Juan L. Iovanna, Aurélie Bedel, Pierre Dubus, Isabelle Moranvillier, Sandrine Dabernat, Evelyne Peuchant, Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Animalerie A2, Université Bordeaux Segalen - Bordeaux 2, Histologie et Pathologie Moléculaire, Plate-forme de vectorologie, CHU Bordeaux [Bordeaux], Tumorothèque de Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), This work was supported by grants from the Ligue contre le cancer (Comité Dordogne and Comité Landes), the Institut National du Cancer (INCa), France and funding from the SFR Transbiomed (formerly IFR66)., BMC, Ed., Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Cancer Research ,Cellular differentiation ,Cell ,Intracellular Space ,Gene Expression ,Ligands ,Mice ,0302 clinical medicine ,Genes, Tumor Suppressor ,0303 health sciences ,STAT ,Tumor suppressor ,musculoskeletal system ,3. Good health ,Gene Expression Regulation, Neoplastic ,Phenotype ,medicine.anatomical_structure ,MAP kinases ,Oncology ,030220 oncology & carcinogenesis ,Molecular Medicine ,[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,Signal transduction ,Tyrosine kinase ,Carcinoma, Pancreatic Ductal ,Signal Transduction ,musculoskeletal diseases ,congenital, hereditary, and neonatal diseases and abnormalities ,Transplantation, Heterologous ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Biology ,Models, Biological ,03 medical and health sciences ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Cell Line, Tumor ,Pancreatic cancer ,[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,medicine ,Animals ,Humans ,Receptor, Fibroblast Growth Factor, Type 3 ,Oncogene ,030304 developmental biology ,Cell growth ,Research ,Epithelial Cells ,medicine.disease ,Pancreatic Neoplasms ,stomatognathic diseases ,Cell culture ,FGFR3 ,Immunology ,Cancer research - Abstract
Background Due to frequent mutations in certain cancers, FGFR3 gene is considered as an oncogene. However, in some normal tissues, FGFR3 can limit cell growth and promote cell differentiation. Thus, FGFR3 action appears paradoxical. Results FGFR3 expression was forced in pancreatic cell lines. The receptor exerted dual effects: it suppressed tumor growth in pancreatic epithelial-like cells and had oncogenic properties in pancreatic mesenchymal-like cells. Distinct exclusive pathways were activated, STATs in epithelial-like cells and MAP Kinases in mesenchymal-like cells. Both FGFR3 splice variants had similar effects and used the same intracellular signaling. In human pancreatic carcinoma tissues, levels of FGFR3 dropped in tumors. Conclusion In tumors from epithelial origin, FGFR3 signal can limit tumor growth, explaining why the 4p16.3 locus bearing FGFR3 is frequently lost and why activating mutations of FGFR3 in benign or low grade tumors of epithelial origin are associated with good prognosis. The new hypothesis that FGFR3 can harbor both tumor suppressive and oncogenic properties is crucial in the context of targeted therapies involving specific tyrosine kinase inhibitors (TKIs). TKIs against FGFR3 might result in adverse effects if used in the wrong cell context.
- Published
- 2013
- Full Text
- View/download PDF
10. In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens
- Author
-
Miguel Taillepierre, Pierre Dubus, Véronique Guyonnet-Duperat, Benoit Rousseau, Hubert de Verneuil, Aurélie Bedel, Marie Lafitte, Isabelle Moranvillier, François Moreau-Gaudry, Evelyne Peuchant, Sandrine Dabernat, BMC, Ed., Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2 - Institut National de la Santé et de la Recherche Médicale (INSERM), Animalerie 2, Université Bordeaux Segalen - Bordeaux 2 - SFR TransBioMed, Plate-forme de vectorologie, Université Bordeaux Segalen - Bordeaux 2, and This work was supported by grants from the Ligue contre le cancer (Comité Dordogne), the Institut National du Cancer (INCa), France and funding from the SFR Transbiomed (formerly IFR66).
- Subjects
Cancer Research ,medicine.medical_treatment ,viruses ,Green Fluorescent Proteins ,Mice, SCID ,Biology ,Malignancy ,Thymidine Kinase ,lcsh:RC254-282 ,Viral vector ,Targeted therapy ,Mice ,Viral Proteins ,Drug Delivery Systems ,Antigen ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,In vivo ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Luciferases ,Ganciclovir ,Mucin-4 ,Research ,Lentivirus ,Gene Transfer Techniques ,Gene targeting ,Genetic Therapy ,Suicide gene ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Xenograft Model Antitumor Assays ,Pancreatic Neoplasms ,Oncology ,Antigens, Surface ,Claudins ,Gene Targeting ,Cancer research ,Adenocarcinoma ,Molecular Medicine ,[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,Surface marker ,Pancreatic adenocarcinoma ,Carcinoma, Pancreatic Ductal - Abstract
Background Pancreatic ductal adenocarcinoma is a deadly malignancy resistant to current therapies. It is critical to test new strategies, including tumor-targeted delivery of therapeutic agents. This study tested the possibility to target the transfer of a suicide gene in tumor cells using an oncotropic lentiviral vector. Results Three cell surface markers were evaluated to target the transduction of cells by lentiviruses pseudotyped with a modified glycoprotein from Sindbis virus. Only Mucin-4 and the Claudin-18 proteins were found efficient for targeted lentivirus transductions in vitro. In subcutaneous xenografts of human pancreatic cancer cells models, Claudin-18 failed to achieve efficient gene transfer but Mucin-4 was found very potent. Human pancreatic tumor cells were modified to express a fluorescent protein detectable in live animals by bioimaging, to perform a direct non invasive and costless follow up of the tumor growth. Targeted gene transfer of a bicistronic transgene bearing a luciferase gene and the herpes simplex virus thymidine kinase gene into orthotopic grafts was carried out with Mucin-4 oncotropic lentiviruses. By contrast to the broad tropism VSV-G carrying lentivirus, this oncotropic lentivirus was found to transduce specifically tumor cells, sparing normal pancreatic cells in vivo. Transduced cells disappeared after ganciclovir treatment while the orthotopic tumor growth was slowed down. Conclusion This work considered for the first time three aspect of pancreatic adenocarcinoma targeted therapy. First, lentiviral transduction of human pancreatic tumor cells was possible when cells were grafted orthotopically. Second, we used a system targeting the tumor cells with cell surface antigens and sparing the normal cells. Finally, the TK/GCV anticancer system showed promising results in vivo. Importantly, the approach presented here appeared to be a safer, much more specific and an as efficient way to perform gene delivery in pancreatic tumors, in comparison with a broad tropism lentivirus. This study will be useful in future designing of targeted therapies for pancreatic cancer.
- Published
- 2012
- Full Text
- View/download PDF
11. HRAS germline mutations impair LKB1/AMPK signaling and mitochondrial homeostasis in Costello syndrome models
- Author
-
Laetitia Dard, Christophe Hubert, Pauline Esteves, Wendy Blanchard, Ghina Bou About, Lyla Baldasseroni, Elodie Dumon, Chloe Angelini, Mégane Delourme, Véronique Guyonnet-Dupérat, Stéphane Claverol, Laura Fontenille, Karima Kissa, Pierre-Emmanuel Séguéla, Jean-Benoît Thambo, Lévy Nicolas, Yann Herault, Nadège Bellance, Nivea Dias Amoedo, Frédérique Magdinier, Tania Sorg, Didier Lacombe, and Rodrigue Rossignol
- Subjects
Metabolism ,Medicine - Abstract
Germline mutations that activate genes in the canonical RAS/MAPK signaling pathway are responsible for rare human developmental disorders known as RASopathies. Here, we analyzed the molecular determinants of Costello syndrome (CS) using a mouse model expressing HRAS p.G12S, patient skin fibroblasts, hiPSC-derived human cardiomyocytes, a HRAS p.G12V zebrafish model, and human fibroblasts expressing lentiviral constructs carrying HRAS p.G12S or HRAS p.G12A mutations. The findings revealed alteration of mitochondrial proteostasis and defective oxidative phosphorylation in the heart and skeletal muscle of CS mice that were also found in the cell models of the disease. The underpinning mechanisms involved the inhibition of the AMPK signaling pathway by mutant forms of HRAS, leading to alteration of mitochondrial proteostasis and bioenergetics. Pharmacological activation of mitochondrial bioenergetics and quality control restored organelle function in HRAS p.G12A and p.G12S cell models, reduced left ventricle hypertrophy in CS mice, and diminished the occurrence of developmental defects in the CS zebrafish model. Collectively, these findings highlight the importance of mitochondrial proteostasis and bioenergetics in the pathophysiology of RASopathies and suggest that patients with CS may benefit from treatment with mitochondrial modulators.
- Published
- 2022
- Full Text
- View/download PDF
12. Cellular Uptake of ODNs in HIV-1 Human-Infected Cells A Role for Viral Particles in DNA Delivery.
- Author
-
Mathieu Métifiot, Aurélie Faure, Véronique Guyonnet-Duperat, Pantxika Bellecave, Simon Litvak, Michel Ventura, and Marie-Line Andréola
- Published
- 2007
13. Cellular uptake of ODNs in HIV-1 human-infected cells: a role for viral particles in DNA delivery?
- Author
-
Marie-Line Andreola, Aurelie Faure, Simon Litvak, Mathieu Métifiot, Véronique Guyonnet-Duperat, Michel Ventura, Pantxika Bellecave, Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Laboratory of Molecular Pharmacology, National Institutes of Health [Bethesda] (NIH)-National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH), CNRS UMR 5097, Plate-forme de vectorologie, Université Bordeaux Segalen - Bordeaux 2-SFR TransBioMed, Service de virologie et unité de surveillance biologique [Bordeaux], and CHU Bordeaux [Bordeaux]
- Subjects
[SDV]Life Sciences [q-bio] ,Cell ,Oligonucleotides ,HIV Integrase ,Biology ,Virus ,Flow cytometry ,law.invention ,Cell Line ,HeLa ,03 medical and health sciences ,0302 clinical medicine ,law ,Genetics ,medicine ,Humans ,HIV Integrase Inhibitors ,Molecular Biology ,ComputingMilieux_MISCELLANEOUS ,030304 developmental biology ,Fluorescent Dyes ,0303 health sciences ,Microscopy, Confocal ,medicine.diagnostic_test ,Virion ,hemic and immune systems ,respiratory system ,biology.organism_classification ,Flow Cytometry ,Molecular biology ,3. Good health ,Integrase ,medicine.anatomical_structure ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,Cell culture ,030220 oncology & carcinogenesis ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Recombinant DNA ,biology.protein ,HIV-1 ,Molecular Medicine ,Intracellular ,HeLa Cells - Abstract
We have previously described how a 16 nucleotides ODN (termed 93del) is capable of inhibiting the activity of recombinant integrase in a cell-free system as well as HIV-1 replication in human-infected cells with IC(50) in the low nanomolar range. Intracellular HIV-1 replication was inhibited when the ODN was added at the onset of infection. These results raise several questions. Is a naked ODN able to enter the cell? Does the virus play a role in ODN entry? The uptake of several ODNs (93del, 60del(sc), TBA, T30923) was evaluated and then tracked by labeling the ODN with a fluorescent dye and assessing its intracellular localization by confocal microscopy. A significant level of cellular uptake of free ODN was observed in several cell lines: HeLa epithelial cells, Huh7 hepatic cells, and H9 lymphocytes, and was detected for all ODNs tested except for TBA. Striking differences were observed when naked ODNs were added to cell in the presence or absence of the virus. When HIV-1 virions were present a sharp increase in cellular fluorescence was observed. These results strongly suggest a role for HIV-1 virions in the uptake of certain ODNs.
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.